Clinical trials: Chimeric Antigen Receptor T-cell Therapy
B-ALL
Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL
The purpose of this study is to evaluate the safety and efficiency of autologous CD19/CD22 CAR-T lymphocytes in a cohort of pediatric and young adult patients with relapsed /refractory B-lineage acute lymphoblastic leukemia
- Trial name
- NCT04499573
- Testing
- CD19/CD22 CAR-T
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis
Safety and Efficacy of S103 Cells in Progressive/Refractory Multiple Sclerosis
This study is a single-center, open-label, single-arm, exploratory clinical study to evaluate the safety, tolerability, and preliminary efficacy of S103（BCMA-CAR T ）cells in the treatment of progressive or refractory multiple…
- Conditions
- Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis, Multiple Sclerosis (MS) Secondary Progressive, Refractory Multiple Sclerosis
- Trial name
- RESET-MS (NCT07587125)
- Testing
- S103 cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Xijing Hospital
Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia
CAR19PK is a research study evaluating the use of lymphodepleting chemotherapy and chimeric antigen receptor (CAR) T cell therapy, a type of cellular therapy, for the treatment of refractory and/or relapsed leukemia.
- Trial name
- NCT06847269
- Testing
- Fludarabine, Cyclophosphamide, Mesna
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- St. Jude Children's Research Hospital
Acute Lymphoblastic Leukemia
A Retrospective Study of Patients With Leukemia Relapse in the CNS Treated With CAR T Cells
CAR T cells targeting CD19 have been approved for patients with relapsed or refractory ALL, failing two or more prior protocols.
- Trial name
- NCT04158011
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Sheba Medical Center
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma
This is an open-label study to determine the safety of anti-B-cell maturation antigen (BCMA) Chimeric antigen receptor T-cell (CAR T) therapy in participants with Relapsed or Refractory Multiple Myeloma (RRMM).
- Trial name
- NCT05577000
- Testing
- Manufactured Anti-BCMA CAR-T cells, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Thomas Martin, MD
B-cell Acute Lymphoblastic Leukemia
A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)
This is a multi-center, phase I/II trial to evaluate the safety and efficacy of HY004 treatment in Adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-cell ALL).
- Trial name
- B-ALL (NCT06009107)
- Testing
- HY004, Cyclophosphamide, Fludarabine Phosphate
- Sponsor
- Juventas Cell Therapy Ltd.
Classical Hodgkin Lymphoma
CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma
Patients with relapsed low-risk CD30 classical Hodgkin Lymphoma will have autologous CD30 CAR T-cell manufactured. Dose escalation will be used to determine the RP2D. Following lymphodepletion, CAR T-cell will be infused.
- Trial name
- REACH-CD30 (NCT07575893)
- Testing
- CD30+ CAR T-cells, Bendamustin, Fludarabine
- Volunteers
- 12 people
- Sponsor
- New York Medical College
B-Cell Acute Lymphoblastic Leukemia, Adult
Allogeneic UCB-derived CAR-T for B-ALL
The purpose of this clinical trial is to learn if allogeneic, umbilical cord blood-derived chimeric antigen receptor T-cell (UCAR-T) therapy works to treat B-cell acute lymphoblastic leukemia (B-ALL) in adults.
- Trial name
- NCT07256353
- Testing
- allogeneic umbilical cord blood-derived CAR-T
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The General Hospital of Western Theater Command
Acute Lymphobkastic Leukemia, B Cell Lymphoma
This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.
The purpose of this study is to estimate the safety and the efficacy of anti-CD19/22 CAR- T cells immunotherapy for adults with relapsed or refractory acute lymphoblastic leukemia/lymphoma.
- Trial name
- MSTH-CAR002 (NCT07162571)
- Testing
- CD19/22 CAR-T cells
- Where
- Belarus
- Volunteers
- 17 people
- Sponsor
- Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
Multiple Myeloma, Multiple Myeloma in Relapse
UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to determine if UF-KURE-BCMA (B-Cell Maturation Antigen) chimeric antigen receptor T cells (CAR-T cells) can be used to treat relapsed or treatment refractory multiple myeloma (RRMM).
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
- Trial name
- NCT06698744
- Testing
- UF-KURE-BCMA CAR T-cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Sponsor
- David Wald
Solid Tumor, Adult, Colorectal Cancer
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer
- Trial name
- BASECAMP-1 (NCT04981119)
- Testing
- Apheresis, Next Generation Sequencing (NGS), Long Range NGS HLA typing
- Where
- 16 sites in United States
- Volunteers
- 500 people
- Sponsor
- A2 Biotherapeutics Inc.
Chronic Lymphocytic Leukemia, Non-hodgkin Lymphoma
huCART19-IL18 in CD19+ Cancers
The purpose of this study is to evaluate the safety and feasibility of huCART19-IL18 cells in patients with relapsed or refractory CD19+ cancers.
- Conditions
- Chronic Lymphocytic Leukemia, Non-hodgkin Lymphoma, Acute Lymphoblastic Leukemia
- Trial name
- NCT04684563
- Testing
- huCART19-IL18
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Pennsylvania
Solid Tumors
Clinical Study on the Safety and Efficacy of B7H3 CAR T Cells in Patients With B7H3 Positive Solid Tumors
This single-arm, single-center investigator-initiated trial (IIT) evaluates the safety, efficacy, and pharmacodynamic (PD)/pharmacokinetic (PK) profiles of CAR-T cells in patients with advanced solid tumors.
- Trial name
- NCT07152236
- Testing
- CAR-T
- Where
- China
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd
Myelodysplastic Syndrome
Study of an Innovative Therapy Using CAR-T Cells Targeting IL-1RAP in Patients With High-Risk Myelodysplastic Syndromes (MDS
The surface protein IL-1RAP, expressed by leukemic blast cells, represents a target of interest for patients with acute myeloid leukemia (AML).
- Trial name
- RAPSODIE (NCT07455500)
- Testing
- Bone marrow and blood sampling
- Volunteers
- 120 people
- Sponsor
- University Hospital, Grenoble
Sarcoma
Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma
Patients have a type of cancer called sarcoma. Because there is no standard treatment for the patients cancer at this time or because the currently used treatments do not work fully in all cases, patients are being asked to…
- Trial name
- NCT00902044
- Testing
- Autologous HER2-specific T cells, Fludarabine, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Baylor College of Medicine
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes
The purpose of this study is to evaluate the safety, efficacy and blood kinetics of autologous T cells genetically modified to express anti-CD19 Chimeric Antigen Receptor in patients with relapsed or refractory B-Cell Non-Hodgkin…
- Trial name
- NCT02134262
- Testing
- Cyclophosphamide or Bendamustine, Dose Level -1, Dose Level 1
- Where
- Japan
- Volunteers
- 18 people
- Sponsor
- Jichi Medical University
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory
Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies
This is a phase l, single arm, prospective open, dose-escalation study in patients with relapsed or refractory CD19-positive B cell malignancies (ALL, NHL, CLL). The trial will include adult and pediatric patients.
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory
- Trial name
- CARTHIAE-1 (NCT05705570)
- Testing
- Cyclophosphamide, Fludarabine, Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day 0
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Nelson Hamerschlak
Lymphoma, Non-Hodgkin
Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL
Although the anti-CD19 CAR-T cell therapies have gained significant results in patients with relapsed and refractory B-cell hematologic malignancies.
- Trial name
- NCT04638270
- Testing
- anti-CD19 FasT CAR-T cells
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Xinqiao Hospital of Chongqing
Recurrent Glioblastoma, Refractory Glioblastoma
Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma
This is a pilot phase I, single-center, open-label, single-arm study to evaluate the feasibility, safety, tolerability, and preliminary efficacy of repeated intracranial infusions of BP102 in adults with recurrent or refractory…
- Trial name
- NCT04385173
- Testing
- BP102 (B7-H3 CAR-T)
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Acute Lymphoblastic Leukemia
CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study
This clinical study investigates a novel treatment option for adolescents and adults with acute B-lymphoblastic leukemia (B-ALL).
- Trial name
- NCT07072494
- Testing
- CD19 CAR-T cells injection
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Zhujiang Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.